ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of…
Read More
Strados Labs Collaborates with Beth Israel Deaconess Medical Center for Innovative Study in Pulmonary Edema The study will evaluate continuous lung sound monitoring for the early detection of pulmonary edema and prevention of complications in critically ill ICU patients. by Strados Labs | Feb 20, 2025 | Press Releases Philadelphia, PA, February 20, 2025 —…
Read More
IVIEW Therapeutics Announces Topline Results from Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe for Dry Eye Disease CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical trial evaluating 2 concentrations…
Read More
The New Yorker: The Long Quest for Artificial Blood One of the most valuable substances in the world has never been replicated. Are we close? By Nicola Twilley See more here
Read More
Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™ Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced its…
Read More
IVIEW Therapeutics Completed A++ Round Financing to Advance its innovative Ocular Drug Development Programs IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced the successful completion of its A++ round of financing. The funds raised will primarily be used to advance…
Read More
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies Publication reports 10% of participants wereither "Much Improved" or "Very Much Improved" as rated by the Clinician…
Read More
Ossianix Receives Grant from The Michael J. Fox Foundation to Advance TXP1 Brain Shuttle for Delivering TrkB Agonist Antibody in Parkinson’s Disease Therapy by PS, 09 Jan, 2025 Stevenage, UK – 9 January 2025 – Ossianix Inc., an antibody discovery and engineering company with a CNS focus, has been awarded…
Read More
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of cutaneous venous malformations (cutaneous VMs)…
Read More
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101 Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria’s proprietary Senza5 platform that features CD5 modulation and a proprietary 5-day manufacturing…
Read More